Ondansetron versus metoclopramide for managing hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trials.
Ondansetron
hyperemesis gravidarum
metoclopramide
nausea
vomiting
Journal
Turkish journal of obstetrics and gynecology
ISSN: 2149-9322
Titre abrégé: Turk J Obstet Gynecol
Pays: Turkey
ID NLM: 101656661
Informations de publication
Date de publication:
27 Jun 2022
27 Jun 2022
Historique:
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
ppublish
Résumé
This investigation examined the efficacy of ondansetron (intervention) versus metoclopramide (control) in managing parturient females with hyperemesis gravidarum (HG), by pooling data from randomized controlled trials (RCTs) using a meta-analysis approach. From inception until January 2022, five information sources were screened: Cochrane Central Register of Controlled Trials, Google Scholar, Scopus, PubMed and Web of Science. Quality assessment was done through the Cochrane Risk of Bias (version 2) assessment tool. The mean difference (MD) with 95% confidence interval (CI) was used to summarize the continuous data in a fixed- or random-effects model, depending on the extent of between-study heterogeneity. Five RCTs were included, comprising a total of 695 patients (355 and 340 females were assigned to ondansetron and metoclopramide, respectively). Four RCTs had an overall "low" risk of bias, whereas one RCT had an overall "some concerns" due to lack of sufficient information about randomization. There was no significant difference between both groups regarding the pregnancy-unique quantification of emesis and nausea score [MD=0.23, 95% CI (-0.42, 0.88), p=0.49], length of hospital stay [MD=-0.17 days, 95% CI (-0.35, 0.02), p=0.08], the number of doses of drug received [MD=0.45, 95% CI (-0.08, 0.98), p=0.10], and duration of intravenous fluids [MD=-1.73 hours, 95% CI (-5.79, 2.33), p=0.40]. Among parturient females with HG, there was no substantial difference in efficacy between both agents. Nevertheless, ondansetron is favored over metoclopramide in view of its trending therapeutic efficacy and better safety profile.
Identifiants
pubmed: 35770443
doi: 10.4274/tjod.galenos.2022.14367
pmc: PMC9249360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
162-169Informations de copyright
©Copyright 2022 by Turkish Society of Obstetrics and Gynecology, Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Ann Intern Med. 2014 Dec 16;161(12):JC3
pubmed: 25506875
Clin Exp Obstet Gynecol. 2013;40(1):127-30
pubmed: 23724526
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Obstet Gynecol Surv. 2019 Mar;74(3):161-169
pubmed: 31634919
Gastroenterol Clin North Am. 2011 Jun;40(2):309-34, vii
pubmed: 21601782
Cochrane Database Syst Rev. 2020 Oct 19;10:CD012859
pubmed: 33075160
PLoS One. 2021 Sep 20;16(9):e0257584
pubmed: 34543335
N Engl J Med. 2013 Feb 28;368(9):814-23
pubmed: 23445092
Obstet Gynecol. 2014 Jun;123(6):1272-1279
pubmed: 24807340
Pharmacology. 2017;100(3-4):161-171
pubmed: 28641304
J Emerg Med. 2010 Sep;39(3):330-6
pubmed: 20022195
Drug Saf. 1998 Aug;19(2):155-64
pubmed: 9704251
JAMA Netw Open. 2021 Apr 1;4(4):e215329
pubmed: 33890993
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Birth Defects Res. 2020 Aug;112(13):996-1013
pubmed: 32420702
J Matern Fetal Neonatal Med. 2020 Apr;33(8):1405-1411
pubmed: 30173590
Obstet Gynecol. 2002 Jul;100(1):94-100
pubmed: 12100809
Emerg (Tehran). 2015 Fall;3(4):137-40
pubmed: 26495402
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
BMJ. 2011 Jun 17;342:d3606
pubmed: 21685438
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Birth Defects Res A Clin Mol Teratol. 2012 Jan;94(1):22-30
pubmed: 22102545
J Perianesth Nurs. 2008 Oct;23(5):292-9
pubmed: 18926476
Ann Med Surg (Lond). 2022 Jan 11;74:103248
pubmed: 35070292
J Matern Fetal Neonatal Med. 2018 Sep;31(18):2492-2505
pubmed: 28614956